Perioperative Analgesia and Postoperative Nausea and Vomiting Management in Otoplasty: A Systematic Review

Abstract

Background:

Effective perioperative analgesia and control of postoperative nausea and vomiting (PONV) are key determinants of recovery after otoplasty for prominent ear deformity, yet comparative evidence for current techniques is limited.

Methods:

A PROSPERO-registered systematic review (CRD42024586119) was performed in September 2024 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Google Scholar, Web of Science, and the Cochrane Library were searched (1989–2020) for English-language randomized or prospective studies reporting pain outcomes after otoplasty. Nine studies (6 randomized controlled trials and 3 cohort studies; 370 patients) met eligibility criteria. Two reviewers extracted pain scores, opioid use, PONV, and complications; risk of bias was assessed using RoB 2 and methodological index for non-randomized studies.

Results:

Regional nerve block provided superior analgesia versus local infiltration anesthesia with a mean pain score at 6 hours of 0.25 versus 2.34 (P < 0.001) and opioid requirements of 14% versus 24%. Propofol anesthesia and transdermal hyoscine patches reduced PONV to 16% versus 48% with placebo. Reported adverse events were infrequent (<5%) and transient (eg, Horner syndrome, mild bradycardia, hoarseness). Overall methodological quality was moderate, and heterogeneity precluded meta-analysis.

Conclusions:

Regional nerve block is the most effective strategy for perioperative pain control in otoplasty, halving opioid use and improving early pain scores. Adjunctive propofol and hyoscine further reduce PONV, with no serious or lasting complications. Standardized multimodal protocols and high-quality trials—especially in pediatric and awake procedures—are required to strengthen evidence and broaden applicability.

Takeaways

Question: Does a long-acting regional nerve block plus targeted antiemetic prophylaxis improve perioperative pain and nausea outcomes in otoplasty compared with conventional lidocaine infiltration?

Findings: A systematic review of 9 prospective studies (6 randomized controlled trials, 370 patients) found that bupivacaine nerve blocks reduced 6-hour pain (numeric rating scale 0.25 versus 2.34) and opioid use (14% versus 24%) compared with lidocaine infiltration; propofol or transdermal hyoscine halved vomiting (16% versus 48%). Reported complications were infrequent (<5%) and self-limited.

Meaning: Combining a long-acting nerve block with evidence-based antiemetics may provide a safer, more comfortable recovery after otoplasty.

INTRODUCTION

Otoplasty primarily addresses protruding ear deformities, the most common congenital auricular anomaly. This condition affects approximately 5% of the population and often follows an autosomal dominant inheritance pattern.¹ In 2022, the American Society of Plastic Surgeons reported approximately 8000 cosmetic otoplasty procedures among 13- to 19-year-olds, ranking below rhinoplasty and breast procedures.² Such deformities—including prominent and lop-ear anomalies—can significantly impair self-esteem and psychosocial well-being, so surgical correction is often a priority for affected individuals.³

Perioperative pain management is a critical component of otoplasty, as inadequate analgesia can impede wound healing, exacerbate stress responses, and increase the risk of chronic postsurgical pain.^4–6 Effective control of acute surgical pain not only enhances patient satisfaction but also promotes adherence to postoperative care regimens, thereby improving overall outcomes.⁶

Current pain‐management strategies in otoplasty include regional nerve blocks (RNBs), local anesthesia, and systemic medications. Regional analgesia typically targets the auricular branch of the great auricular nerve and the lesser occipital nerve via injections at the mastoid process, posterior to the auricle. Agents such as bupivacaine or lidocaine with adrenaline provide extended analgesia throughout the perioperative period, reducing both pain intensity and postoperative nausea and vomiting (PONV).⁷ These blocks are simple, well tolerated, and can minimize systemic analgesic use, especially in pediatric patients who are more susceptible to pain and nausea.¹

Despite the availability of multiple analgesic techniques, substantial gaps persist in the literature. Most studies focus on isolated interventions, such as single nerve blocks or pharmacological agents, rather than evaluating comprehensive, multimodal strategies that incorporate both pharmacological and nonpharmacological approaches.⁸ Furthermore, comparative studies of regional versus local anesthesia remain limited, especially in pediatric otoplasty patients, where age-specific pain responses and recovery dynamics must be carefully considered.⁹ The long-term effects of analgesic strategies on chronic postsurgical pain, patient satisfaction, and functional recovery are not well characterized. Adjunctive therapies such as acupuncture and mindfulness-based interventions, though supported in broader surgical contexts, have been minimally explored in otoplasty, despite evidence suggesting they may reduce perioperative pain and opioid reliance.¹⁰

Study Objective

This systematic review and meta-analysis aimed to evaluate the effectiveness of various perioperative pain control techniques in otoplasty compared with alternative approaches or no intervention. The study focused on pain control and relief, incidence of adverse outcomes, patient satisfaction, and recovery duration.

METHODS AND MATERIALS

This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines¹¹ and was registered in PROSPERO (CRD42024586119). PubMed, first 20 pages of Google Scholar, Web of Science, and the Cochrane Library were searched from the inception of databases to September 30, 2024, using (otoplasty OR ear surgery OR auricular correction) AND (pain management OR analgesia OR pain control). We limited the eligibility to the studies published between 2014 and 2024 because the past decade encompasses the introduction of long-acting local anesthetics, ultrasound-guided regional blocks, and enhanced-recovery protocols, thereby providing the most clinically relevant evidence. Titles, abstracts, and full texts were screened.

Eligibility Criteria

Inclusion

The inclusion criteria were English-language human studies; randomized controlled trials (RCTs), prospective/retrospective cohort, or case-control designs; otoplasty patients; a clearly described perioperative pain management protocol; and reporting of at least 1 predefined outcome. Single-arm observational series that reported 1 or more outcomes were also eligible, because the paucity of controlled trials in otoplasty analgesia makes such descriptive data valuable; these studies were synthesized narratively and analyzed separately from comparative trials.

Exclusion

The exclusion criteria were non-English publications; animal/cadaver studies; case reports, systematic reviews, conference abstracts, case series with fewer than 5 patients, or non–peer-reviewed work; studies without otoplasty patients or without an analgesic protocol; and studies lacking a comparator arm.

Study Selection

All references were imported into Rayyan.¹² Four reviewers independently screened titles/abstracts; conflicts were resolved by discussion. Full texts were assessed by 2 reviewers, with a third-reviewer arbitration when necessary. Inter-rater reliability for full-text inclusion was evaluated on 72 records (Fleiss κ = 0.03); pair-wise Cohen κ ranged from 0.10 to 0.35 (mean 0.21). All disagreements were resolved by consensus.

Data Extraction

Two reviewers extracted study characteristics, patient demographics, analgesic details (agent, dose, timing), and outcomes. Outcomes were defined as any measurable perioperative clinical endpoint, including postoperative pain intensity (visual analog scale [VAS] or numeric rating scale [NRS]), opioid consumption, incidence of PONV, patient-reported satisfaction, and recovery indices such as time to discharge. Analgesic efficacy denotes the reduction in pain intensity scores attributable to the intervention, whereas patient satisfaction reflects self-reported comfort and overall contentment with pain management. All entries were cross-checked to avoid duplication.

Risk of Bias

RCTs were appraised using the Cochrane RoB 2 tool and observational studies using methodological index for non-randomized studies (MINORS).^13,14 Discrepancies were resolved by consensus.

RESULTS

The search yielded 925 records; after removing duplicates, 752 titles and abstracts were screened. Sixteen full-text articles were assessed for eligibility, and 9 studies published between 1989 and 2020 satisfied all criteria (Fig. 1). These comprised 6 RCTs and 3 prospective observational studies (Tables 1–3). Collectively, they enrolled 370 patients with a mean age of roughly 16 years; 41% were men, and few had notable comorbidities.

Fig. 1.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses chart illustrating the screening results of the systematic reviews and meta-analyses.

Table 1.

Key Characteristics of the 9 Studies Included in the Systematic Review

No.	Author, Year	Study Design	N (pts)	Age Range/Mean	Main Intervention(s)	Comparison/Control	Key Outcomes Measured	FU	Country	Comorbidities Reported
1	Burtles, 198915	Controlled trial	63	Mean 9 y	Great auricular nerve block (bupivacaine)	No nerve block	Pain, vomiting, recovery indices	24 h	Scotland	No comorbidity
2	Roberts et al, 199216	Double-blind controlled trial	30	3–19 y	Lidocaine + bupivacaine injection	None	Pain scores (details NR)	24 h	New Zealand	No comorbidity
3	Paxton et al, 199517	RCT (double-blind)	60	3–14 y	Ondansetron 0.1 mg kg−1 IV (preoperative)	Droperidol, placebo	Emesis rate, time-to-oral intake	24 h	N. Ireland/United Kingdom	None specified
4	Honkavaara et al, 199518	Double-blind RCT	50	Mean 9.3 y	Hyoscine transdermal patch 0.5 mg	Placebo patch	PONV, sedation, complications	24 h	United Kingdom	No comorbidity
5	Cregg et al, 19967	RCT	43	3–15 y	RNB (bupivacaine 0.5%)	LIA	Pain, opioid use, PONV	24 h	Ireland	None specified
6	Woodward et al, 199719	Single-blind RCT	30	4–14 y	Propofol infusion	Thiopentone/isoflurane	PONV, recovery time, pain	24 h	United Kingdom	No comorbidity
7	Kakagia et al, 200520	Prospective double-blind comparative	24	19–43 y	Ropivacaine versus bupivacaine (bilateral model)	—	Pain scores, analgesic efficacy	24 h	Greece	None specified
8	Santos, 201321	Prospective cohort	38	14–48 y	Local anesthesia with sedation	Local anesthesia without sedation	Pain, satisfaction, cost-effectiveness	12 mo	Brazil	None specified
9	Kepekçi and Kepekçi1	RCT	32	17–41 y	RNB	LIA	Pain scores, opioid use, complications	24 h	Turkey	None specified

FU, follow-up duration after surgery; IV, intravenous; NR, not reported in abstract/figure snapshot.

Table 3.

MINORS Quality Scores for the 3 Nonrandomized Prospective Studies

Total/24	19	18	20
Statistical analyses	2	2	2
Baseline equivalence	2	1	2
Contemporary groups	2	2	2
Control group	2	2	2
Prospective sample size calculation	0	0	0
Loss < 5%	2	2	2
Adequate FU*	2	2	2
Unbiased assessment	1	1	2
Endpoints appropriate	2	2	2
Prospective data collection	2	2	2
Inclusion of consecutive patients	0	0	0
Clearly stated aim (0/1/2)	2	2	2
Design	Prospective comparative	Prospective comparative	Prospective single-blind, RCT-like
Study ID	Kakagia et al20	Santos21	Woodward et al19

^*Adequate follow-up (FU) was scored “2” when ≥ 24 hours for perioperative outcomes or 12 months in Santos²¹ for cost-effectiveness.

RNB consistently delivered more durable pain control than local infiltration anesthesia (LIA) in every head-to-head study (Table 4). Two trials recorded statistically significant reductions in NRS scores within the first 12 hours, accompanied by lower rescue opioid use.^1,7 Bupivacaine-based RNB dominated preoperative practice, whereas postoperative care relied chiefly on paracetamol—often paired with an nonsteroidal anti-inflammatory drug.^1,7,19 Where duration was reported, a single RNB injection provided 8 hours or more of analgesia^1,7; subsequent oral or parenteral drugs were administered only as needed.^1,7,19 This extended coverage reflects bupivacaine’s slower dissociation from axonal Na⁺ channels, whereas lidocaine, the agent most often used for LIA, typically wears off after 2–4 hours.¹⁶ In the sole direct infiltration trial, 0.25% bupivacaine halved early opioid rescue (2 of 15 versus 7 of 15 children in the first 4 h) and maintained effective analgesia for 8 hours or more, whereas 1% lidocaine lost effect within 4 hours despite similar late-evening pain scores.¹⁶ Because the comparator was a short-acting drug, this result is vulnerable to “duration bias,” favoring the molecule rather than the infiltration technique itself.¹⁶

Table 4.

Preoperative and Postoperative Analgesic/Antiemetic Protocols Reported in the 9 Otoplasty Studies

Author, Year	Preoperative Pain/PONV Management	Postoperative Analgesia	Dose/Frequency	Expected Duration of Effect*
Burtles, 198915	Great auricular nerve block (bupivacaine)	Diamorphine, paracetamol	Single preoperative block; PRN opioids	Up to 8 h
Roberts et al, 199216	Lidocaine + bupivacaine digital block	Morphine, paracetamol	Single infiltration; PRN opioids	4–8 h
Paxton et al, 199517	Ondansetron 0.1 mg kg−1 IV	Paracetamol ± minimal opioids	Single preoperative dose	≈ 24 h
Honkavaara et al, 199518	Transdermal hyoscine patch 0.5 mg (antiemetic)	Diclofenac, paracetamol, oxycodone	One patch applied preoperatively; oral/IV PRN	Patch ≈ 72 h
Cregg et al, 19967	RNB with bupivacaine 0.5%	Paracetamol ± rescue opioids	Single preoperative block	≈ 24 h
Woodward et al, 199719	Propofol infusion (induction + maintenance)	Morphine, diclofenac, paracetamol	Per procedure; multimodal PRN	≈ 24 h
Kakagia et al, 200520	Local soft-tissue infiltration (ropivacaine + bupivacaine)	No systemic drugs required	One intraoperative injection	Up to 8 h
Santos, 201321	Local anesthesia with IV sedation	Same local anesthesia without sedation	Single session	Followed for 12 mo†
Kepekçi and Kepekçi, 20201	Ultrasound-guided RNB	Dexketoprofen PRN	RNB once preoperatively; NSAID as needed	≈ 24 h

^*“Duration” reflects either the manufacturer-quoted anesthetic window (for nerve blocks/LIA) or the postoperative observation period used by the authors.

^†Santos²¹ followed patients for economic and satisfaction endpoints for 12 months after the single perioperative session.

IV, intravenous; NSAID, nonsteroidal anti-inflammatory drug; PRN, as needed.

PONV were also ameliorated by specific interventions. Transdermal hyoscine patches¹⁸ and maintenance anesthesia with propofol¹⁹ each reduced vomiting rates by about one-half relative to placebo or thiopentone/isoflurane, respectively. Honkavaara et al¹⁸ reported that a 0.5-mg transdermal hyoscine patch reduced vomiting from 48% to 16% versus placebo, but produced short-lived blurred vision, dizziness, and bradycardia in less than 10% of children, almost all resolving within 2 hours, except for 1 case.

Adverse events were uncommon and transient. Cervical plexus blocks occasionally produced mild hoarseness or self-limiting Horner syndrome–like symptoms,¹ and hyoscine patches were associated with brief visual disturbance or bradycardia in a small number of children.¹⁸ Notably, hyoscine’s anticholinergic sequelae (blurred vision, dizziness, transient bradycardia) resolved within 2 hours, whereas RNB-related events were even rarer and equally self-limiting, underscoring the favorable safety margin of regional techniques; however, no permanent complications were reported.^1,18

Hospital discharge generally occurred within 24 hours. Same-day discharge was more frequent when propofol, RNB, or local anesthetic with sedation formed part of the regimen,^1,19,21 whereas overnight observation was usual after conventional inhalational anesthesia or exclusive reliance on LIA.^7,15,17

Risk-of-bias assessment indicated that 4 of the 6 RCTs were at low risk, and 2 had some concerns, chiefly related to performance bias (Table 2). Observational studies achieved MINORS scores of 18–20 out of 24, reflecting moderate methodological quality (Table 3). Taken together, the evidence indicates that RNB confers superior analgesia with a concomitant reduction in opioid use and PONV, all within an acceptable safety profile; detailed numeric outcomes are fully presented in Tables 1–4.

Table 2.

Cochrane RoB 2 Judgement for the 6 Randomized Trials

Study ID	Selection Bias	Performance Bias	Detection Bias	Attrition Bias	Reporting Bias	Other	Overall Risk
Burtles15	?	?	?	Low	Low	Low	Some concern
Roberts et al16	?	Low	Low	Low	Low	Low	Low/some concern
Honkavaara et al18	?	Low	Low	Low	Low	Low	Low/some concern
Paxton et al17	?	High	Low	Low	Low	?	Some concern/high*
Cregg et al7	?	Low	Low	Low	Low	Low	Low/some concern
Kepekçi and Kepekçi1	Low	Low	Low	Low	Low	Low	Low

^*Bold text indicates high risk of bias. High because of open-label antiemetic versus placebo; “some concern” indicates ≥1 unclear domain but no confirmed high-risk item.

DISCUSSION

We conducted a systematic review of perioperative analgesia in otoplasty and found that RNBs are consistently associated with lower early pain scores and reduced opioid use compared with LIA. Two commonly targeted nerves are the auriculotemporal and the superficial cervical plexus branches^22,23 (Figs. 2, 3).

Fig. 2.

The anatomical path of the auriculotemporal nerve as it arises from the mandibular nerve, encircles the middle meningeal artery, and ascends superiorly.²²

Fig. 3.

The superficial branches of the cervical plexus (lesser occipital, great auricular, transverse cervical, and supraclavicular nerves) emerging from the posterior border of the sternocleidomastoid at the nerve point of the neck.²³

In the Kepekçi and Kepekçi¹ RCT, RNB delayed pain onset (10.5 versus 3.5 h) and lowered the 6-hour NRS (0.25 versus 2.34; P < 0.001) relative to LIA. These results, although significant, should be interpreted cautiously because the trial enrolled only 35 patients. The pharmacological advantage derives from bupivacaine’s slower voltage-gated Na⁺ channel off-rate (τ ≈ 50 versus ≈ 10 min for lidocaine), producing a 4- to 8-hour sensory block and explaining the “duration bias” noted by Roberts et al.^16,24,25

Cregg et al⁷ likewise reported fewer opioid requirements with RNB (14% versus 24%) despite comparable pain scores, although the difference was not powered for statistical testing. In bilateral cases, Kakagia et al²⁰ found similar analgesic efficacy for bupivacaine and ropivacaine but highlighted ropivacaine’s lower cardiotoxicity, making it preferable in high-risk patients.²⁰ Taken together, the evidence supports RNB as the preferred technique for sustained analgesia in otoplasty, with multiple studies demonstrating clinically—and in several trials statistically—meaningful benefits over LIA.^1,7,24

Postoperative Nausea and Vomiting

PONV emerged as the most troublesome complication in the general anesthesia–based otoplasty studies we reviewed. Volatile anesthetics and intraoperative opioids activate the chemoreceptor trigger zone, thereby increasing the emetogenic load compared with awake or purely local techniques.^26,27 Targeted prophylaxis—chiefly transdermal hyoscine or total intravenous anesthesia with propofol—substantially mitigated this risk.²⁸

In a double-blind pediatric RCT, Honkavaara et al¹⁸ showed that a 0.5-mg hyoscine patch reduced vomiting from 48% to 16% (P < 0.05). Likewise, Woodward et al¹⁹ reported that propofol maintenance anesthesia produced only 1 episode of nausea and 3 of vomiting, versus 8 and 10, respectively, after thiopentone/isoflurane. Propofol also accelerated recovery: mean time to eye-opening was 6.3 minutes compared with 11.7 minutes in controls.¹⁹ Hyoscine’s anticholinergic sequelae (blurred vision, dizziness, transient bradycardia) were short-lived, and no irreversible neurovascular or infectious events were documented after more than 200 regional blocks, underscoring the favorable safety profile of both strategies.^19,26

Combining Analgesic and Antiemetic Techniques

High-level evidence indicates that the greatest perioperative benefit is achieved when RNB is paired with targeted antiemetic prophylaxis. Although no single trial assessed this combination head-to-head, findings from separate RCTs are complementary: RNB outperformed local infiltration for pain control,^1,7 whereas transdermal hyoscine¹⁸ and propofol maintenance¹⁹ each halved PONV. Taken together, these data support a multimodal pathway that couples long-acting regional anesthesia with an evidence-based antiemetic.

The present synthesis also clarifies that lidocaine-based local infiltration (1% with adrenaline 1:200,000) provides useful intraoperative analgesia, yet is consistently inferior to RNB at 6–12 hours postoperatively—an interval in which bupivacaine RNB still confers sensory blockade, opioid-sparing, and higher comfort scores.²⁰ RNB’s safety profile was favorable: transient dysphonia or Horner-like signs resolved within hours, and no serious neurovascular events were reported. Conversely, hyoscine patches, though effective, produced reversible anticholinergic effects (blurred vision, dry mouth, dizziness) in a minority of children.¹⁸ Propofol reduced both PONV incidence and emergence time relative to thiopentone/isoflurane but requires infusion pumps and vigilant hemodynamic monitoring, factors that may limit use in low-resource settings.^4,19

Local pinna infiltration remains simple and cost-effective,⁷ yet where expertise and resources permit, the weight of current evidence supports an RNB + antiemetic bundle. Wider adoption could standardize care and improve recovery metrics, but implementation studies are needed to confirm feasibility across diverse practice environments. In resource-constrained units, cost analyses comparing single-shot RNB plus oral ondansetron to propofol or hyoscine protocols would be valuable.

In summary, RNB—preferably with long-acting bupivacaine—combined with either propofol anesthesia or transdermal hyoscine currently represents the most evidence-backed strategy for minimizing pain, opioid exposure, and PONV after otoplasty. Broad, multisite RCTs directly testing these combinations versus standard care are the next research priority.

Limitations

Several factors temper the strength and generalizability of this review. Marked clinical and methodological heterogeneity—spanning local anesthetic concentrations, adjunct dosing and timing, pain scales (VAS versus NRS), and PONV definitions—meant that predefined pooling thresholds for meta-analysis were not met, so a narrative synthesis was required. Meta-analysis was not appropriate because the studies did not use consistent methods to define or measure the outcome. When pain and PONV were assessed using different scales, timepoints, or definitions, any pooled estimate would risk obscuring real differences or falsely suggesting equivalence. Direct, head-to-head comparisons were scarce, small, or single-center, restricting the precision of effect estimates and limiting between-study triangulation. All 9 trials were conducted under general anesthesia; therefore, results may not extrapolate to awake or office-based otoplasty, where baseline emetogenic load is lower. Sample sizes were modest (median = 32 participants) and follow-up rarely exceeded 24 hours, inhibiting detection of infrequent adverse events or chronic pain sequelae. Reporting was inconsistent: many studies omitted randomization details, failed to stratify outcomes by known PONV modifiers (sex, smoking status, Apfel risk), and used nonstandard satisfaction metrics. Language restriction to English raises potential publication bias, and the search strategy may have missed relevant gray literature. Finally, the single lidocaine-versus-bupivacaine trial is subject to “duration bias,” as distinct Na⁺-channel binding kinetics confound any anatomical effect, and the favorable safety signal for transdermal hyoscine derives from just 1 pediatric RCT. Collectively, these limitations highlight the need for adequately powered multicenter RCTs using standardized enhanced recovery after surgery protocols, uniform outcome measures, and inclusion of awake techniques to refine perioperative analgesia and antiemetic strategies in otoplasty.

Recommendations

Future work should prioritize adequately powered multicenter RCTs that compare RNB with LIA across diverse age groups—including pediatric and geriatric patients—to refine analgesic protocols for otoplasty. Investigators should use standardized outcome instruments such as the VAS for pain and the Apfel risk score for PONV, and they should report key patient-level modifiers (eg, sex, smoking status) to enhance external validity. Larger sample sizes, rigorous CONSORT-compliant reporting, and uniform follow-up will help reduce bias and permit meta-analysis. Finally, the exploration of ultrasound-guided RNB, long-acting local anesthetics, and multimodal PONV-prevention bundles (propofol maintenance, transdermal hyoscine, nonopioid adjuncts) may further improve perioperative care and patient outcomes.

CONCLUSIONS

RNB emerges as the current preferred technique based on available evidence for perioperative pain management in otoplasty, offering prolonged analgesia, reduced opioid consumption, and enhanced patient satisfaction compared with LIA. Complementary strategies, such as propofol for anesthesia induction and transdermal hyoscine for PONV prophylaxis, further improve recovery outcomes. Although serious complications are rare (eg, transient Horner syndrome, bradycardia), their self-resolving nature underscores the safety of these interventions. Limitations in current evidence—heterogeneous methodologies, small sample sizes, and underrepresentation of pediatric populations—highlight the need for rigorous, standardized trials. Future research should prioritize multimodal approaches, ultrasound-guided techniques, and international collaboration to refine protocols and ensure equitable, evidence-based care across diverse patient demographics.

DISCLOSURE

The authors have no financial interest to declare in relation to the content of this article.

ETHICS APPROVAL

Ethical approval was not required for this systematic review, as it used data from previously published studies only.